Summary of included studies evaluating the effectivity of neuroprotectants in ischemic strokes
| Source | No. of patients | Age (mean) | Baseline NIHSS (mean) or stroke severity | Initiation of medications | Dose | Route | Follow-up period |
|---|---|---|---|---|---|---|---|
Muresanu et al. (2016) [14] | 208 | 64.0 | 10.4 | Within 24 h to 72 h after the onset of stroke | 30 mL cerebrolysin in PNSS once a day for 21 days | IV infusion | 90 days |
Heiss et al. (2012) [15] | 908 | 65.3 | 16.4 | Within 12 h after the onset of stroke | 30 mL cerebrolysin in PNSS once a day for 10 days | IV infusion | 90 days |
Gharagozli et al. (2017) [16] | 100 | 67.8 | 11.1 | Within 18 h after the onset of stroke | 30 mL cerebrolysin in PNSS once a day for 7 days then 10 mL until day 30 | IV infusion | 30 days |
Stan et al. (2017) [17] | 60 | 64.3 | 10.0 | Within 24 h to 48 h after the onset of stroke | 30 mL cerebrolysin in PNSS once a day for 10 days | IV infusion | 30 days |
Lang et al. (2013) [18] | 119 | 66.3 | 11.65 | Within 30 min from rtPA administration | 30 mL cerebrolysin in PNSS once a day for 10 days | IV infusion | 90 days |
Clark et al. (1999) [19] | 394 | 70.5 | 13.0 | Within 24 h after the onset of stroke | 500 mg CDP-choline once daily for 6 weeks | Oral intake | 6 weeks |
Clark et al. (1997) [20] | 259 | 67.8 | 12.85 | Within 24 hours after stroke onset | 500 mg, 1,000 mg, and 2,000 mg CDP-choline daily in 1–2 doses daily for 6 weeks | Oral intake | 12 weeks |
Dávalos et al. (2012) [21] | 2,298 | 72.9 | 15.0 | Within 24 h after the onset of stroke | 1,000 mg CDP-choline IV in PNSS twice a day for 3 days then 1,000 mg tab twice a day for a total of 6 weeks | IV infusion for 3 days then oral intake for a total of 6 weeks | 90 days |
Clark et al. (2001) [22] | 899 | 67.5 | 14.2 | Within 24 h after the onset of stroke | 1,000 mg CDP-choline twice daily for 6 weeks | Oral intake | 6 weeks |
Sun et al. (2019) [23] | 130 | 51.9 | 22.2 | During admission | 30 mg edaravone in PNSS twice daily for 14 days | IV infusion | 14 days |
Sharma et al. (2011) [24] | 50 | 57.1 | 10.3 | Within 6 h to 72 h after the onset of stroke | 30 mg edaravone in PNSS twice daily for 14 days | IV infusion | 90 days |
EAISG (2003) [25] | 250 | 66.2 | Mild to moderate | Within 72 h after the onset of stroke | 30 mg edaravone in PNSS twice daily for 14 days | IV infusion | 12 months |
Chen et al. (2013) [26] | 1,100 | 61.4 | 8.7 | Within 72 h after the onset of stroke | 4 capsules MLC601 3 times daily for 3 months | Oral intake | 3 months |
Venketasubramanian et al. (2017) [27] | 880 | 61.8 | 8.6 | Within 72 h after the onset of stroke | 4 capsules MLC601 3 times daily for 3 months | Oral intake | 2 years |
Harandi et al. (2011) [28] | 150 | 65.3 | Mild to moderate | Within 1 month after the onset of stroke | 4 capsules MLC601 3 times daily for 3 months | Oral intake | 12 months |
PNSS: plain normal saline solution; IV: intravenous; EAISG: Edaravone Acute Infarction Study Group
